A study of a GLP-1 medicine, semaglutide.

Recruiting now. Registry record last updated February 18, 2026.

Who can join: Adults 18+, have weight gain, BMI 27+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor The University of Texas Health Science Center, HoustonDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 30

What this study is for

Primary condition: Weight Gain.

Full scientific study title: Incretin Microdosing for Cardiometabolic Health in People With HIV.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have weight gain, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Confirmed human immunodeficiency virus type 1 (HIV-1)
On antiretroviral therapy (ART) for greater than or equal to 24 weeks prior to entry and no change in regimen in the 12 weeks prior to entry or planned change for the study duration
HIV-1 ribonucleic acid (RNA) \<200 copies/mL at screening
BMI greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 if also with greater than or equal to 1 weight-related comorbidity
If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for greater than or equal to 12 weeks prior to entry and no plans to dose escalate for the study duration

Key exclusion criteria

Weight greater than or equal to 400 pounds \[due to dual X-ray absorptiometry (DXA) machine limitations\] or unexplained weight change greater than or equal to 5% in the 12 weeks prior to entry
Diagnosis of or on treatment for diabetes mellitus (stable metformin dosing for pre-diabetes not excluded)
Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period
Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period
Active eating disorder

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site

The University of Texas Health Science Center at Houston
Houston, Texas
Jordan E Lake, MD, MSc713-500-6767Jordan.E.Lake@uth.tmc.edu

Follow this trial

We email you if NCT07325500 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: February 12, 2026. Expected completion: June 30, 2029. Last updated on ClinicalTrials.gov: February 18, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.